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Abstract. Recent advances in DNA profiling techniques have enabled sensitive detection of tumor-associated genomic
aberrations in peripheral blood. This type of minimally-invasive molecular interrogation has the potential to guide subsequent
treatment selection. The potential utility of ctDNA in bladder cancer (BC) is bolstered by the high somatic mutation rate,
meaning that very small numbers of genes or target regions can be informative. First reports indicate that analysis of ctDNA
may represent a sensitive method for disease surveillance in patients with different stages of BC. Moreover, recent evidence
suggests that ctDNA analysis reveals previously unknown genomic alterations in metastatic patients. Since some of these
gene alterations represent therapeutic targets, ctDNA analysis provides an attractive tool to guide individualized therapy
in BC.
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INTRODUCTION
The analysis of tumor-associated genomic alter-
ations in circulating tumor DNA (ctDNA) is
rapidly developing as a platform for biomarker
discovery in patients with advanced malignancies
[1, 2]. Initial studies of ctDNA in the 1970s
described an association between ctDNA burden
and tumor aggressiveness [3], but progress was
hampered by technological constraints. However,
advances in digital droplet polymerase chain reac-
tion (PCR) and highly sensitive next-generation
sequencing (NGS) now allow capture and analysis of
ctDNA even when highly diluted by non-malignant
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cell-free DNA (cfDNA) [4, 5]. Recent studies of
several solid cancers suggest that somatic alter-
ations detected in ctDNA are reflective of those
present in matched tumor tissue: proposing ctDNA-
based profiling as a practical method to assess
the tumor genome independently of direct tissue
analysis [4, 6]. This holds particular promise in
patients with relapsed or metastatic disease who
rarely undergo biopsy of recurrent or metastatic
lesions.
Emerging data suggests that ctDNA analysis will
augment the management of patients with bladder
cancer (BC) [7–10]. Our review summarizes recent
progress and preliminary data supporting clinical
utility of ctDNA in BC. In particular, we high-
light the remarkable potential for ctDNA to aid
disease surveillance across different stages of BC
and the power of ctDNA to provide insights into the
metastatic BC genome in real-time.
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METHODS
We reviewed current literature nonsystematically
using the National Library of Medicine database
(http://www.pubmed.gov). A Medline search was
performed using the following terms: urothelial car-
cinoma, bladder cancer, liquid biopsy, cell free DNA,
circulating tumor DNA, cfDNA, ctDNA. Articles
were considered between 2010 and 2017. Refer-
ences were also secondarily extracted from identified
articles. In addition, recent studies presented at the
Annual Meeting of the American Society for Clinical
Oncology (ASCO) were included.
DETECTION OF CTDNA:
METHODOLOGIC CONSIDERATIONS
Fragments of cell-free DNA (cfDNA) are shed
into the circulation by both tumor cells and non-
malignant cells, especially hematopoietic cells [11].
The enduring challenge for accurate profiling of the
tumor-derived proportion of cfDNA, is that the rela-
tive quantity of ctDNA varies significantly by disease
state and between patients. Unlike a direct tissue
biopsy where a pathologist can estimate tumor cellu-
larity prior to genomic profiling, the ctDNA fraction
of any given plasma cfDNA sample is much less
predictable. Clues can be drawn from a patient’s
overall disease burden since ctDNA fractions cor-
relate with clinical metrics of tumor volume such
as serum alkaline phosphatase or lactate dehydroge-
nase [12]. In metastatic patients where the ctDNA
fraction can be above 50% of all cfDNA, the total
extracted DNA yield from plasma can also inform on
ctDNA fraction [10]. However, in patients with low
disease volume or those with minimal residual dis-
ease after therapy, ctDNA may be extremely rare or
not be present at all in a small plasma sample. It is
important to note that the lower bound for detecting
ctDNA is governed by the total amount of cfDNA
obtained. In our recent study, the average cfDNA
yield in patients with localized muscle-invasive blad-
der cancer (MIBC) not receiving therapy was less
than 10 ng per mL of plasma (representing approxi-
mately 1500 diploid genomes) [10]. This means that,
even with the latest technologies, for ctDNA to be
realistically detected in 1–2 mL of plasma, it must
be present at fractions above 1/1500.
In most studies to date, alterations in ctDNA have
been detected using either polymerase chain reaction
(PCR)-based methods or targeted next-generation
sequencing approaches (NGS; Table 1). The selection
of the most appropriate method for cfDNA analysis
must consider cost, number of genomic alterations
and tumor burden. It is not possible to maintain cost-
effectiveness while simultaneously informing upon
both very low ctDNA fractions and a broad panel of
genomic regions. Therefore, approaches are typically
tailored for the disease state (and ctDNA fraction) in
question. Assays specifically capturing known muta-
tions permit the detection of mutant alleles in patients
with ctDNA fractions of 0.01 to 1% [8, 13]. Of course,
this must be enabled by either patient-specific a pri-
ori knowledge (e.g. from archival tissue profiling)
or plausible presence of recurrent single nucleotide
mutations (e.g. PIK3CA p.E545K). Droplet digital
PCR (ddPCR) or bead-based PCR has been used
well to this end, but is challenging to multiplex
beyond a handful of mutations [7–9]. Similarly, ultra-
deep NGS incorporating unique molecular identifiers
(UMIs), also known as barcodes, can reveal very
‘diluted’ mutations across entire genes, but, due to
the high sequencing depth required, costs escalate
quickly if scaled beyond a few genes [14]. Impor-
tantly however, because of the very high mutation
rate in MIBC, both methodologies are suitable and
even a very small targeted panel could be effective.
For example, over 90% of MIBC patients have at
least one mutation in the hotspot regions of PIK3CA,
the promoter region of TERT, or the TP53 gene, so
a panel covering just those regions can still expect to
be informative in most MIBC patients [10, 15, 16].
Broader next-generation sequencing panels allow
more exploratory analyses of the genomic landscape,
including genes disrupted by copy number changes
and rearrangements (such as FGFR3 fusions) [10].
At present this approach is likely only relevant for
patients with high ctDNA fractions, such as those
with progressing metastatic disease. Indeed, we have
shown that whole exome sequencing yields robust
results in a significant minority of metastatic BC
patients. Unfortunately, with current technology the
detection of single gene copy number changes is
much more challenging at ctDNA fractions less than
20–30%, due to multiplicative noise [6, 17]. Although
shifts in the allelic frequency of germline SNPs can
help identify single copy gains or losses at slightly
lower ctDNA fractions, we can draw lessons from
fetal cfDNA screens of maternal plasma where chro-
mosomal aneuploidies are only confidently ‘called’
at fetal cfDNA fractions above 10%.
Ultimately the technical challenges of cfDNA anal-
ysis must be weighed against those faced by direct
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Table 1
Overview of techniques used for analysis of cell free DNA (cfDNA)
Technique Overview Minimum % of
ctDNA required (of
total cfDNA)
Advantages Disadvantages Ref.
Digital droplet PCR Detection of
previously known
or frequent
mutations/CNVs
(e.g. androgen
receptor in prostate
cancer)
∼0.01 (mutations) High sensitivity, no
NGS platform
required
Limited number of
targets assessable in
parallel
[8, 9, 48]
∼10% (copy number
alterations*)
Ultra-deep
sequenc-ing with
UMIs
Detection of unknown
mutations in 1–10
genes or regions
∼0.01 (mutations) High sensitivity, can
inform on multiple
genes
Either limited to
∼1–10 genes with
coverage of only
few kbps or high
costs in case of
higher coverage
(Mbps)
[14, 27, 49]
Standard targeted
NGS (without
UMIs)
Detection of unknown
mutations/CNVs in
a preselected panel
of genes or regions
2 (i.e. mutation
detection at 1%
VAF); 10–20% for
CNV detection
(varies by nature
and extent of
alteration)
Broad target regions
assessable, low
input required
No detection of low
abundance
mutations
[10, 43, 47]
Standard WES/WGS Detection of unknown
mutations/CNVs
20 Assessment of entire
exome/genome
High ctDNA fraction
required
[10]
CNV: copy number variation; NGS: next generation sequecing; PCR: polymerase chain reaction; SNP: single nucleotide polymorphism;
WES: whole exome sequencing; WGS: whole genome sequencing; VAF = variant allele frequency; UMI = unique molecular identifiers
(barcodes); ∗not yet demonstrated in bladder cancer but shown in other malignancies.
tissue biopsy, which also suffers from variable failure
rates, issues of tumor cellularity, and complications
derived from formalin-fixation. Blood samples are
much more practical to obtain than tissue samples,
and blood-based assays are therefore more easily
scalable to large patient cohorts. Furthermore, in the
event of a negative result (e.g. no ctDNA detected),
repeat sampling is clinically feasible.
USING CTDNA FOR BLADDER CANCER
SURVEILLANCE
The first reports exploring ctDNA in BC employed
ddPCR for highly sensitive detection of distinct
BC-associated mutations in plasma, specifically for
monitoring patients for relapse in the aftermath
of local disease intervention [8, 9]. Birkenkamp-
Demtro¨der et al. demonstrated that low ctDNA
fractions in non-muscle-invasive BC (NMIBC) are
no barrier to ctDNA detection and clinical utility [8].
In their 2016 report, the authors initially employed
WES to identify somatic mutations in primary tumor
tissue resected from each patient tumor. Up to six
patient-specific mutations from each tumor speci-
men were then incorporated into a series of ddPCR
assays capable of detecting one mutated gene allele
from 6000 background copies of the wildtype gene
(<0.02%). With this level of sensitivity the authors
were able to detect ctDNA early in the disease course
in 9 of 12 patients, including patients with Ta dis-
ease. Applying these personalized ddPCR assays
longitudinally, at multiple time points in the course
of each patient’s disease, demonstrated ctDNA was
detectable prior to clinical demonstration of pro-
gression in 4 of 6 patients who ultimately showed
clinical progression (it should be noted that all 12
patients with NMIBC in this study developed dis-
ease recurrence, and the other 6 progressed to muscle
invasive or metastatic disease). Remarkably, in one
patient ctDNA was detected 1 year before clinical
progression, and assay-specific genome equivalents
increased fivefold over this time period. Indeed, aver-
age ctDNA burdens were higher in patients who
progressed than those who simply recurred. Further-
more, the authors also found high levels of tumor
DNA in the urine of all patients with progressive
disease, even in the absence of detectable plasma
ctDNA. The study strongly supports the use of plasma
and urine ctDNA to monitor for BC disease recur-
rence and progression, and is consistent with recent
22 T. Todenho¨fer et al. / Liquid Biopsy
data from breast cancer, where digital PCR assays
for ctDNA detection can predict relapse after local
therapy [4].
Designing personalized ddPCR assays is
extremely labour- and cost-intensive (WES of tissue)
and requires patient tissue. Given the high mutation
rate of some genes in BC, a clear alternative for
detecting low ctDNA fractions (and therefore, resid-
ual disease) is to develop ddPCR assays targeting a
handful of specific genomic alterations with known
recurrence. For example, PI3KCA, TERT, FGFR3,
RAS family members, and TP53 all contain specific
base pairs that are recurrently mutated in BC, known
as mutation ‘hotspots’. Accordingly, the same
Danish group as above applied a non-personalized
ddPCR approach in two retrospective patient cohorts.
One cohort included 363 patients with NMIBC, and
the other included 403 patients undergoing radical
cystectomy for predominantly (90%) MIBC. In this
study, Christensen et al. selected two of the most
commonly mutated genes in BC – FGFR3 and
PIK3CA - and developed ddPCR assays for the sen-
sitive detection of their hotspot mutations [18, 19].
However, these two genes alone are not sufficient to
represent all patients with BC, and therefore only
36% of NMIBC and 11% of cystectomy patients in
this study actually harbored one or both mutations
in their archival tumor tissue. Since only 2 of 7
patients in the NMIBC cohort had detectable ctDNA
at the time of disease progression, the analysis was
not expanded to include all NMIBC patients. In the
cystectomy cohort, ctDNA levels were associated
with recurrence-free and overall survival. The BC
recurred in 8/9 patients with detectable ctDNA but
only 6/18 with no detectable ctDNA. The reduced
detection rate (particularly for NMIBC), likely
reflects the more constrained ddPCR approach, and
would likely be improved with the addition of further
hotspot mutations in other recurrently mutated BC
genes.
The most recent study from the Aarhus group
focused on ctDNA to monitor treatment response
and disease relapse in patients with MIBC. Pre-
designed ddPCR assays were used to screen for
hotspot mutations in PIK3CA and FGFR3 in tissue
samples collected prospectively from 60 patients, of
whom 19 were found to have mutations. In addi-
tion, the authors performed WES in tumor tissue
from 24 of the same patients to develop personalized
ddPCR assays. Combined pre-designed and personal-
ized ddPCR assays were used to monitor 26 patients
undergoing neoadjuvant chemotherapy followed by
radical cystectomy (n = 24) or systemic chemother-
apy for metastatic BC (n = 2). ctDNA was detected
in the plasma of 75% of patients after cystectomy,
which correlated with worse RFS. The median inter-
val between ctDNA detection in plasma and clinical
detection of recurrence was 101 days. A similar early
detection of recurrence by ctDNA ahead of radio-
graphic detection has been reported for other cancer
types [20]. In ten patients with metastatic disease,
the authors observed a clear decrease of ctDNA lev-
els during therapy and an increase after cessation of
therapy, which correlated with radiographic response
to therapy.
While these three contributions offer proof of
principle that plasma ctDNA detected by ddPCR
may be a valuable test for disease surveillance,
the data is relatively heterogenous, and validation
in larger and broader patient cohorts is necessary.
As outlined above, the ddPCR approach is attrac-
tive due to its sensitivity in patients with low
tumor burden, but is limited by the low number of
mutations captured, and does not accommodate for
tumor heterogeneity and molecular evolution over
time.
Further application of this type of assay can be
projected for patients with both NMIBC and MIBC.
Presence versus absence of ctDNA, or relative quan-
tities of ctDNA could be useful for risk stratification.
This could be relevant, for example, in patients with
high grade T1 bladder cancer considering intravesi-
cal therapy versus immediate radical cystectomy. The
administration of adjuvant chemotherapy after radi-
cal cystectomy for MIBC could be influenced by the
presence of ctDNA in the peripheral blood. Detec-
tion of ctDNA could serve as a valuable tool for the
early determination of disease recurrence after radi-
cal cystectomy or trimodal therapy for MIBC, which
in turn would enable administration of early systemic
therapy before metastatic disease becomes apparent
by radiologic imaging.
A natural extension of using ddPCR to monitor for
recurrence and progression in patients with NMIBC
and MIBC is to use if for primary disease detection in
patients with signs or symptoms of BC but no prior
history of BC. Significant efforts are underway to
establish protocols using cfDNA for early and non-
invasive detection of cancer [21]. It is expected that
progress in technical development will significantly
reduce costs of current high-throughput approaches,
which in turn will promote investigations on ctDNA-
based early detection of cancer. In the context of intact
primary bladder cancer, analysis of cfDNA in urine
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offers an additional option for disease detection and
monitoring [4].
Before ctDNA analysis can be implemented in rou-
tine clinical practice to monitor the disease status of
BC patients, prospective studies with larger sample
sizes are required. If studies confirm the potential
of ctDNA analysis to detect recurrence earlier than
current tools (urine markers, cystoscopy and imag-
ing), interventional studies based on ctDNA detection
could be considered. In the case of MIBC, one poten-
tial study design would be to select patients for
adjuvant chemotherapy based on results of ctDNA
analysis early after cystectomy.
MOLECULAR INTERROGATION OF
ADVANCED BC USING CTDNA ANALYSIS
Higher plasma ctDNA fractions allow for a
more extensive characterization of the correspond-
ing tumor genome using NGS. Since ctDNA burden
typically corresponds with disease burden, this type
of analysis is largely restricted to advanced dis-
ease stages [7]. While The Cancer Genome Atlas
Project (TCGA) has provided important insight into
the genomics and biology of MIBC, there is sur-
prisingly few data available for metastatic urothelial
carcinoma [22, 23]. This is in large part due to
the fact that metastatic or recurrent BC is rarely
biopsied in clinical practice. Theoretically, analysis
of plasma ctDNA enables the molecular character-
ization of the metastatic tumor ecosystem without
the need for invasive biopsy. This may be particu-
larly relevant for BC since a recent study analyzing
tissue from multiple metastatic tumor sites of indi-
vidual patients demonstrated marked heterogeneity
between metastases [24]. Furthermore, intra-patient
tumor heterogeneity appeared highest in late-stage
disease, and would be significantly underestimated
using archival primary tissue alone.
A potential advantage of ctDNA analysis is the
ability to detect the combined genomic content of
all clones from all sites of disease in the context of
heterogenous and/or multifocal cancer, provided that
each clone releases DNA into circulation. Branched
clonal evolution has been described for bladder can-
cer and other cancers at different tumor sites and
under the selective pressure of systemic therapy
[24, 25].
A gene panel designed to capture key driver muta-
tions and other actionable alterations in BC, as we
have previously reported, will inevitably miss some
important genomic alterations. However, our panel
captures both truncal and some branch mutations.
The addition of more genes to such a panel requires
increased breadth of sequencing, invariably increases
costs.
Identifying therapeutic targets by next generation
sequencing (NGS) of ctDNA
Only two published studies have reported focused
data on ctDNA NGS in patients with BC. Patel et
al. demonstrated the proof of principle that SNVs
can be measured by Tagged Amplicon Sequenc-
ing and copy number alterations (CNA) by shallow
Whole Genome Sequencing in plasma samples
from 17 patients with MIBC receiving neoadjuvant
chemotherapy [26]. The assay was designed to ana-
lyze SNVs in BRAF, CTNNB1, FGFR3, HRAS,
KRAS, NFE2L2, PIK3CA and TP53, which together
would capture 72% of patients with MIBC in the
original report from the TCGA [22]. Although SNVs
and CNAs were found in 12 and 16, respectively, of
16 tumor samples at baseline, only 6 of 17 patients
had detectable SNVs or CNAs in their ctDNA before
chemotherapy, and 3 additional patients were found
to have alterations during chemotherapy. The most
frequent alteration was a mutation in TP53. The
detection of tumor-associated aberrations in plasma
samples before chemotherapy showed no correlation
with response to NAC.
We recently reported results from combined whole
exome sequencing (WES) and targeted sequenc-
ing of 50 genes relevant to BC in plasma cfDNA
from 51 patients with aggressive BC, including 37
patients with metastatic disease. Using this broad
approach, tumor genomic characterization was lim-
ited to patients with ctDNA fractions above 2% (i.e.
heterozygous mutations present in plasma at 1%
or higher). This mutation detection threshold (1%)
is routinely selected in conventional NGS studies
because it is approximately 10 times the average
background error rate (0.1%) [27]. Accordingly,
although only 14% of patients with localized dis-
ease had plasma ctDNA fractions above 2%, 73%
of patients with untreated metastatic disease exhib-
ited ctDNA above 2% and clear tumor associated
genomic changes. In previous studies using differ-
ent technologic approaches, higher rates of patients
with localized tumors and detectable ctDNA have
been observed showing that our approach has limita-
tions in non-metastatic disease [16]. Among patients
with ctDNA above 2%, the ctDNA fraction relative
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to the total cfDNA in the serum ranged from 3.9%
to a remarkable 72.6% (i.e. more tumor-derived
cfDNA than non-malignant cfDNA in the plasma).
ctDNA fractions exceeding 30% were observed
exclusively in patients with distant metastatic disease.
It seems likely that the majority of ctDNA detected
in metastatic patients was shed by metastatic lesions
(rather than the primary tumor) as we observed no
relationship between cystectomy status and ctDNA
fraction. However, we did not assess whether ctDNA
burden correlates with metastatic tumor burden (e.g.
as assessed by imaging) or number of metastatic
lesions.
In patients receiving chemotherapy, we noted that
total cfDNA yields from plasma were high regard-
less of disease stage. Since ctDNA fractions did not
appear to be concomitantly elevated, we hypothe-
size this could reflect increased cfDNA released by
dying non-malignant cells affected by chemother-
apy. To validate this hypothesis, future studies could
explore the spacing of nucleosome footprints in
cfDNA to identify putative predominant cell-of-
origin. This approach has been shown to enable
a characterization of the origin of cells indepen-
dent of observed genomic alterations [28]. In our
study, the TP53 gene was the most commonly
altered, affected in 65% (17/26) of patients; higher
than the 49% rate observed in the TCGA cohort
[22]. Further cell-cycle associated genes with fre-
quent aberrations included RB1 and CDKN2A. A
high proportion of patients (19/26) showed aber-
rations in at least one chromatin remodeling gene
(including ARID1A and KMT2D). Alterations in
the PI3K/mTOR pathway were observed in a sig-
nificant proportion of metastatic patients. Genomic
alterations in the MAPK pathway were detected in
15/26 patients with evidence of ctDNA, including
nine patients with ERBB2 activating changes (either
hotspot mutations or gene amplifications). Using
capture probes tiled across the introns of FGFR3,
we were able to detect (in multiple samples from
one patient) a previously unreported gene fusion
of FGFR3 and ADD1 potentially leading to over-
activation of FGFR3 (similar to the well-established
FGFR3-TACC3 fusion gene).
The identification of diverse mutations, copy num-
ber changes, and chromosomal rearrangements in our
study suggests that ctDNA may be useful for guid-
ing molecularly targeted therapy in advanced BC.
For example, detection of FGFR3 fusion genes or
ERBB2 amplifications or mutations could identify
patients susceptible to FGFR3 or ERBB2 inhibitors,
respectively [29]. In clinical trials ERBB2 genomic
alterations have been shown to predict sensitivity to a
specific HER2 inhibition [30] and FGFR alterations
also predict response to FGFR inhibition [31, 32].
Moreover, patients with TSC1/TSC2 alterations may
be good candidates for mTOR inhibition (everolimus)
[33]. Whether plasma ctDNA analysis can be used
as a tool for next generation clinical trials, includ-
ing especially umbrella or basket trials, is a matter of
current debate [34]. First trials using ctDNA analy-
sis in this context have been initiated in various solid
malignancies [35].
Markers of response to therapy in ctDNA
Similarly, molecular markers predicting resistance
or response to currently approved drugs may be iden-
tified in ctDNA. For example, detection of mutations
in ERCC2 or other DNA repair genes could be used to
identify patients likely to respond to cisplatin-based
chemotherapy [36–39]. This type of genomic predic-
tion could streamline care to avoid ineffective and
expensive treatments and instead prioritize the most
effective therapies.
Since high mutational load in BC tumor tissue is
proposed as a potential biomarker for patient response
to immune checkpoint blockade, we have suggested
that assessment of the mutation rate using plasma
ctDNA should be tested for its ability to predict
response [40, 41]. In our cohort, 12% of patients had
projected mutation rates above 30 per MB, a threshold
that has been identified in the tissue of other cancers
to be associated with response to immunotherapy. In
a subgroup of patients, we performed WES and com-
pared mutation rates derived from WES with rates
derived from targeted sequencing. Although higher
mutation rates were measured by targeted sequenc-
ing compared to WES, estimated somatic mutation
rates correlated significantly between both methods.
The higher mutation rate in targeted sequencing may
result from a bias towards recurrent driver mutations
in the targeted gene panel, as well as the ability
of deep targeted sequencing to detect low allele
frequency sub-clonal mutations that are missed by
conventional WES. This observation highlights the
need to determine thresholds for ‘high’ mutational
load that are specific to the assay in question. Further-
more, the specific type of mutation, not just overall
mutation rate, may be important. A recent analysis of
5777 solid tumours from 19 cancer types suggested
that insertion or deletion (indel) mutations may be
associated with higher neoantigen immunogenicity
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compared to non-synonymous single nucleotide vari-
ants (SNVs). In a subset of 38 melanoma patients,
higher counts of frameshift indel mutations were
significantly associated with response to PD-1 inhi-
bition [42]. High rates of indels in kidney tumors
may also help explain the responses observed to
immune checkpoint blockade in that cancer type,
despite an overall low mutation rate on average.
Future studies must address these critical knowledge
gaps in BC.
The analysis of plasma samples collected in the
framework of currently ongoing phase III trials
using immunotherapy in urothelial carcinoma will
hopefully provide more insight into a potential cor-
relation between neoantigen burden and response
to immunotherapy. If such a correlation can be
confirmed, prospective interventional trials selecting
treatment type (chemotherapy or immunotherapy)
based on liquid biopsy profiles could be considered.
In a recent study presented at ASCO 2017,
Kuziora et al. analyzed plasma ctDNA using a tar-
geted sequencing panel of 70 genes in 29 patients
with metastatic urothelial carcinoma before treat-
ment and after 6 weeks of treatment with the PD-L1
inhibitor durvalumab in the framework of a phase
II trial [43]. In accordance with our own data, the
genes most frequently altered in pre-treatment sam-
ples were TP53 (73%) and ARID1A (55%). The
authors did not assess mutational burden at base-
line as a predictor of response, as we propose
above, but instead investigated whether changes in
variant allele frequency (VAF) on treatment corre-
lated with response. Compared to baseline, patients
with response to durvalumab showed a significant
decrease in the variant allele frequency after 6 weeks
of treatments (–2.36%, p = 0.02), whereas no signif-
icant changes in VAF were detected in patients with
progressive disease (+2.69%, p = 0.31). Moreover,
patients with response to durvalumab had a decreased
mutation count after 6 weeks of treatment (–4.6
counts, p = 0.003) whereas no significant change was
detected in patients with progressive disease (+2.78
counts, p = 0.436). Patients showing a decrease in the
VAF after 6 weeks had a significantly better PFS and
OS. These data suggest that changes in cfDNA pro-
files detected during an early phase of treatment may
serve as a surrogate parameter of response to treat-
ment and improved outcome. Future studies should
examine whether lack of ctDNA decline on treatment
can be used as a tool to identify patients who will not
respond to a given therapy, and therefore facilitate an
earlier change in therapy
ctDNA in the context of tumor heterogeneity
It is not yet possible to determine whether genomic
aberrations present in the plasma ctDNA originate
from multiple lesions or from a single progressing
lesion. Molecular heterogeneity is as much of a con-
cern in BC as it is in most cancers, such that a putative
target or marker of drug response may only be present
in part of a tumor or in one tumor site [44, 45]. As
described above, the seminal study from Faltas and
colleagues described remarkable intra-patient tumor
heterogeneity in BC [24]. In theory ctDNA could
reflect the totality of all tumor sites, or at least the
predominant tumor clone. Longitudinal testing over
time would allow emerging clones to be identified
promptly. To assess how multiple lesions affect the
profile of ctDNA in patients with metastatic BC,
future studies comparing multiple metastatic sites
and ctDNA will be needed. A rapid autopsy program
could provide a suitable setting for this type of study
[46].
In this context Cheng et al. reported at ASCO
2017 on correlations between ctDNA analysis and
Table 2
Potential applications of ctDNA analysis in patients with different bladder cancer (BC) disease states
Disease State Potential Application of ctDNA References
NMIBC • Screening/Diagnosis [8]
• Risk stratification: Prediction of recurrence/progression [9]
• Prediction of response to intravesical therapy
• Monitoring for recurrence
MIBC • Risk stratification: Prediction of recurrence/survival [26]
• Prediction of response to neoadjuvant chemotherapy [10]
• Decision aide for adjuvant chemotherapy for clinically occult disease (+ctDNA)
• Monitoring for recurrence
Metastatic BC • Determination of mutational load (as putative marker of response to immunotherapy) [10]
• Liquid biopsy for molecular characterization [47]
• Determine presence of target for targeted therapy [43]
• Prediction of response to therapy
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profiling of archival tissue in 15 patients with
metastatic urothelial carcinoma using a capture-
based NGS assay targeting 341–468 genes [47]. In the
whole cohort of patients (n = 26, including patients
with missing archival tissue), at least one somatic
mutation was detected in ctDNA of 69% of patients,
but the same alterations were not present in the tumor
tissue in 40% of cases. On the other hand, 73% of
patients exhibited alterations in archival tissue that
were not detected in plasma. An identical mutation
profile in tissue and plasma was detected in 20% of
patients. The interval between tumor tissue sampling
and plasma sampling in these patients was between
35 days and 1.5 years. These findings underline the
potential added value of plasma ctDNA analysis com-
pared to sequencing of archival tumor tissue, which
might not reflect the current status of disease.
SUMMARY
Bladder cancer exhibits a high mutational burden
compared to other solid tumors. This characteris-
tic means that bladder cancer is particularly suited
for ctDNA analysis, as ‘diluted’ mutant alleles can
now be robustly detected in peripheral blood using
state-of-the-art technologies. In the context of dis-
ease surveillance, initial studies have shown that
specific ddPCR assays facilitate early and highly
sensitive detection of disease recurrence. In patients
with metastatic BC, early targeted NGS studies have
demonstrated that the vast majority of progressing
patients have high levels of ctDNA in their blood and
harbor genomic aberrations that may associate with
differential sensitivity to specific drugs. In addition
to its potential utility in surveillance and identifica-
tion of treatment-relevant genes, ctDNA may also be
a valuable tool for detection of markers of response
to therapy and other components of patient man-
agement (Table 2). This is a burgeoning field of
study with many new discoveries likely in the near
future.
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